Gefitinib Versus Adjuvant Chemotherapy in Patients with Stage II-IIIA Non–Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center …

H Xie, H Wang, L Xu, M Li, Y Peng, X Cai, Z Feng… - Clinical Lung Cancer, 2018 - Elsevier
Background The superior efficacy of first-line treatment with gefitinib over that of standard
chemotherapy was demonstrated in patients with advanced non–small-cell lung cancer …
被引用次数：20 相关文章

Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center …

H Xie, H Wang, L Xu, M Li, Y Peng, X Cai… - Clinical Lung …, 2018 - europepmc.org
Background The superior efficacy of first-line treatment with gefitinib over that of standard
chemotherapy was demonstrated in patients with advanced non-small-cell lung cancer …

Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non–Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center …

H Xie, H Wang, L Xu, M Li, Y Peng… - Clinical Lung …, 2018 - clinical-lung-cancer.com
Background The superior efficacy of first-line treatment with gefitinib over that of standard
chemotherapy was demonstrated in patients with advanced non–small-cell lung cancer …

Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center …

H Xie, H Wang, L Xu, M Li, Y Peng, X Cai… - Clinical lung …, 2018 - pubmed.ncbi.nlm.nih.gov
Background The superior efficacy of first-line treatment with gefitinib over that of standard
chemotherapy was demonstrated in patients with advanced non-small-cell lung cancer …